ClinicalTrials.gg
Biological

Japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) clinical trials

Also written IC51 and IXIARO.

studies test it
18
open now
1
in phase 3
14
first study started
2005

How each study uses japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Mar 2009 · Ixiaro · BLA 125280 (FDA, Purple Book)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Japanese Encephalitis purified inactivated vaccine
6

Brand

IXIARO
6

Development codes

IC51
8

Other names

Japanese Encephalitis vaccine
1

Studies by the year they started

18 studies that test it; most in 2010 (6)

Studies that test japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated), by start year
YearStudies
20055
20061
20072
20082
20106
20121
20221

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
1
Phase 3
14
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 3

Valneva Austria GmbH (15) · Medical University of Vienna (1) · Helsinki University Central Hospital (1) · Singapore General Hospital (1)

Often tested with

Tested in the same studies.

Hepatitis A Vaccines (1) · Japanese Encephalitis Vaccines (1)

Studies

Open first, then newest update. How each study uses japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 18

Given beside what is tested · 1 — japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated)

Codes

What other systems call japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) · ClinicalTrials.gg INT016389

  • UNII (FDA) DZ854I04ZEJAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED)Confirmed FDA, Wikidata
  • Wikidata Q28859737japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)Confirmed FDA, Wikidata
  • NCI Thesaurus C75796Japanese Encephalitis Virus Strain SA 14-14-2 Antigen (Formaldehyde Inactivated)Confirmed FDA, Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.